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Simple Summary: Adolescents and young adults (AYAs, aged 15–39 years) with cancer form a
distinct patient population within the oncology care setting that is often overlooked in favour of
paediatric and older adult patients. As such, specific knowledge on AYAs and their distinct spectrum
of cancers is limited. Worldwide, cancer is increasing and it is among the major causes of death among
AYAs. Cancer prognosis among AYAs has also been shown to lag behind that of younger and older
patients suffering from similar diseases. To address these problems, better understanding of AYA
cancers is needed. This study aims to provide an overview of the specific cancer trends among AYAs
and the changes that have occurred in the Netherlands since 1990 in terms of incidence, survival,
and mortality. This information will provide a solid foundation from which to guide future studies
upon, aimed at acquiring more detailed cancer knowledge within the AYA domain.
Abstract: Adolescent and young adult (AYA) cancer patients, aged 15–39 years at primary cancer
diagnosis, form a distinct, understudied, and underserved group in cancer care. This study aimed
to assess long-term trends in incidence, survival, and mortality of AYA cancer patients within
the Netherlands. Data on all malignant AYA tumours diagnosed between 1990–2016 (n = 95,228)
were obtained from the Netherlands Cancer Registry. European age-standardised incidence and
mortality rates with average annual percentage change (AAPC) statistics and five-year relative survival
rates were calculated. The overall cancer incidence increased from 54.6 to 70.3 per 100,000 person-years
(AAPC: +1.37%) between 1990–2016, and increased for both sexes individually and for most
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cancer types. Five-year relative survival overall improved from 73.7% in 1990–1999 to 86.4%
in 2010–2016 and improved for both sexes and most cancer types. Survival remained poor (<60%)
for rhabdomyosarcoma, lung, stomach, liver, bladder, and pancreatic carcinomas, among others.
Mortality rates among male AYAs overall declined from 10.8 to 6.6 (AAPC: −1.64%) and from
14.4 to 10.1 per 100,000 person-years (AAPC: −1.81%) for female AYAs since 1990. Mortality rates
remained unchanged for male AYAs aged 20–24 and 25–29 years. In conclusion, over the past three
decades, there has been a considerable increase in cancer incidence among AYAs in the Netherlands.
Meanwhile, the survival improved and the mortality overall declined. Survival at five-years now
well exceeds above 80%, but did not do so for all cancer types.
Keywords: adolescents and young adults; AYA; incidence; survival; mortality; cancer epidemiology;
cancer trends; The Netherlands
1. Introduction
Worldwide, adolescents and young adults (AYA) form a distinct, understudied, and underserved
group within the oncology domain that is often overlooked [1–4]. In the Netherlands care for children
with cancer is centralised based on their age, 0–17 years at diagnosis, whereas patients 18 years or
older are being treated in any hospital in the Netherlands and centralisation only takes place based on
certain tumour types. However, in practice this distinction is less clear, as was illustrated by a recent
Dutch study, which observed that children before the age of 18 and diagnosed with (young) adult type
tumours (e.g., chronic myeloid leukaemia, thyroid carcinomas, and melanoma and skin carcinomas)
are less often referred for treatment to a specialised paediatric oncology centre [5]. To improve this,
the nationwide AYA “young & cancer” care network (https://ayazorgnetwerk.nl) was established in
2016 and has made it their main mission to raise national awareness and to optimise the quality and
access to care received by AYAs with cancer in the Netherlands. Nevertheless, care for the AYA age
group is challenging at a global level due to low numbers and specific age adjusted care needs beyond
the primary cancer diagnosis.
The definition of AYA for cancer purposes has evolved over time. In 2006, a broad age range of
15–39 years was proposed by the United States (US) National Cancer Institute (NCI) with support from
the LIVESTRONG Foundation [1], which has been adopted by The European Network for Cancer in
Children and Adolescents.
AYA cancers form a unique spectrum of malignancies comprised of the tail end of cancers frequently
found in children (e.g., acute lymphatic leukaemia, Ewing sarcoma), cancers that primarily affect
older adults (e.g., colorectal, lung, and breast carcinomas) and cancers specific to the AYA population
(e.g., Hodgkin lymphoma, melanoma, germ cell tumours, and thyroid carcinomas). Although rare,
cancer at AYA age is 4–6 times more frequently diagnosed when compared to cancers diagnosed
in children during the first 15 years of life [6,7]. Each year, an estimated 66,000 AYAs will develop
cancer in Europe alone, representing 4% of all invasive cancer diagnoses [6,7]. The incidence of AYA
cancers is increasing in most countries worldwide, including the US and United Kingdom, with sharp
increases in incidence observed for thyroid, testicular, and obesity-related cancers (e.g., colorectal,
uterus, pancreas, gallbladder, and liver) [8,9].
Cancer is responsible for approximately 25% of all deaths at AYA age, making it the leading cause
of disease-related death in this population in high-income countries. Still, improvements in the survival
rate of several cancer types among AYAs are encouraging and overall survival rates now well exceed
80% at five-years of follow-up [10,11]. Previously, it was shown that gains in survival among AYAs
lagged behind those found in children (aged < 15 years) and older adults (aged ≥ 39 years) [12,13],
but according to a recent study (1988–2014), this gap has been closed [14]. Nevertheless, there is still
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much outcome heterogeneity between the various cancer types among AYAs, with the prognosis of
some still lagging considerably behind those found in paediatric and adult patients.
The societal and economic impact of cancer at AYA age is great given the major effects of
premature morbidity and mortality [15]. To improve cancer-associated outcomes for AYAs, the NCI and
LIVESTRONG Foundation released a report in 2006 on AYA oncology entitled “Closing the gap” [1].
An update on the scientific gaps and opportunities for future research on AYAs was provided in a 2013
workshop entitled “Next Steps for Adolescents and Young Adult Oncology: A Scientific Update” [7].
To guide future research efforts, both workshops highlighted the importance of continuing to monitor
cancer trends and recommended the examination of the unique incidence and survival trends of cancer
in general and for individual cancer types by sex, age, and other subgroups within the AYA population
when sample size allows [1,7]. This study aimed to assess long-term trends in incidence, survival,
and mortality of AYA cancer in the Netherlands between 1990–2016 for the total population and by sex,
age group and cancer type.
2. Materials and Methods
2.1. Data Sources
Data on primary cancer incidence and survival were obtained from the nationwide
population-based Netherlands Cancer Registry (NCR), which includes data on all newly diagnosed
cancer cases in the Netherlands since 1989 with exception of basal cell carcinomas of the skin.
The NCR is hosted by the Netherlands Comprehensive Cancer Organisation (IKNL) and is based on
notification of all newly diagnosed malignancies in the Netherlands by the Automated Pathological
Archive (PALGA), supplemented by notifications from the Dutch hospital database and various
haematology laboratories. Following notification, trained registrars collect relevant information on
patient and tumour characteristics from the medical records 6–12 months after diagnosis. All cancers
included in the NCR are coded using the International Classification of Diseases for Oncology
(ICD-O). Cancers diagnosed before 1993 were coded using the first edition of the ICD-O. Between 1993
and 2000, the second edition of the ICD-O was used and since 2001, the ICD-O third edition [16].
Information on vital status (e.g., alive, dead) and emigration was obtained by annual linkage of the
NCR with the nationwide Personal Records Database (BRP; Basisregistratie personen) that holds
vital statistics on all residents in the Netherlands. Mortality data on malignant cancer (ICD-10 code
C00-C97) for the period 1990–2016 were obtained from the cause-of-death statistics of Statistics
Netherlands (http://statline.cbs.nl).
2.2. Data Selection
All malignant neoplasms (ICD-O-3 behaviour code /3) and pilocytic astrocytoma’s (ICD-O-3 M9421,
behaviour code /1) in patients aged 15–39 years and diagnosed between 1990 and 2016 were extracted
from the NCR. From this selection, we excluded low-grade chondrosarcomas, myelodysplastic
syndromes, Langerhans cell tumours, borderline ovarian tumours and carcinomas of the appendix,
as these groups were not consistently coded as malignant tumours throughout the entire study period.
All malignant neoplasms were classified according to the Surveillance, Epidemiology, and End Results
Program (SEER) AYA site recode classification scheme, adapted from the classification scheme proposed
by Barr et al. [17]. Additionally, the international rules concerning multiple cancers were applied to
allow comparison of the results with other studies [18].
2.3. Statistical Analyses
Descriptive analyses of the average number of new cases per year and cancer type distribution,
including all main AYA cancer sites and carcinomas, were performed.
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2.3.1. Age Standardised Rates
Annual and period specific incidence and mortality rates for the period 1990–2016 were calculated
per 100,000 person-years using the mid-year population size obtained from Statistics Netherlands
(http://statline.cbs.nl). Rates were age-standardised with weights based on the five-year age groups
from the 1976 European standard population [19].
2.3.2. Joinpoint Regression Analyses
Changes in incidence and mortality over the entire study period 1990–2016 were evaluated with
joinpoint regression analyses by calculating average annual percentage change (AAPC) statistics and
corresponding 95% confidence intervals (CIs) [20]. All age-standardised incidence and mortality rates
and AAPC estimates were calculated using the freely available Joinpoint Regression Program version
4.8.0.1 [21]. All models were plotted using the “grid search method” and the “uncorrelated error
model”. The number of points to place between adjacent observed x-values in the grid search method
was set at 3 (0 at default). Correlation of the random errors in the data were analysed by repeating
the analyses multiple times, each time with a different value of the autocorrelation parameter (0.1,
0.2, and 0.3). Outcomes were similar to those obtained with the uncorrelated error model, which was
then selected for the final analyses, as correcting for autocorrelation can reduce the power to detect
joinpoints. A minimum of zero and a maximum of five joinpoints was allowed. Selection of the final
model was done using the recommended Bayesian information criteria 3. Further parameters within
the joinpoint program were kept at their default setting.
2.3.3. Relative Survival
Relative survival was used as estimator for disease-specific survival and is the ratio of the observed
survival in cancer patients by the expected survival in a comparable general population matched
by sex, age, and calendar year. Expected survival lifetables of the Dutch general population were
retrieved from Statistics Netherlands and contained annual survival probability data for both sexes
aged 0–99 years between 1950–2019. Five-year relative survival estimates were determined using the
Ederer II method and were computed using the -Strs- Stata command developed by Dickman and
colleagues [22]. End of follow-up was defined as date of death, date of emigration, or 1 February 2019,
whichever came first. Survival trends over time were assessed by modelling the relative survival
using a generalised linear model and assuming a Poisson distribution for the observed number of
deaths [23]. Significance of linear trends, were obtained with p-values from a likelihood ratio test
comparing a model including the midpoint of the calendar period and a model without calendar
period. A p-value < 0.05 was considered to be statistically significant.
Analyses were performed with Stata version 16.1. Outcomes of the various analyses are presented
for all AYAs combined and according to age group (15–19, 20–24, 25–29, 30–34, and 35–39 years),
sex (male, female), calendar period (1990–1999, 2000–2009, 2010–2016, and 1990–2016), and cancer type
whenever feasible. The study was approved by the Privacy Review Board of the NCR. The data used
in this study can be reasonably requested from the NCR (study number K16.305, www.iknl.nl).
3. Results
3.1. Study Population
Table 1 shows the total and average number of new cancer cases, incidence rates and AAPCs by
sex, age, cancer type and calendar period. In total, 95,228 primary AYA cancers were registered in the
Netherlands between 1990–2016. More than half were diagnosed among females (59.0%, n = 56,190).
The total number of AYA cases diagnosed with cancer increased substantially with age from 5.7%
(n = 5434) in AYAs aged 15–19 years to 41.8% (n = 39,798) in AYAs aged 35–39 years (Table 1).
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Table 1. Total and average number of new cancer cases per year, incidence rates and average annual percentage change (AAPC) estimates of all adolescents and young
adults (AYAs) aged 15–39 years at time of diagnosis in the Netherlands between 1990–2016.
Population Characteristics Total Number
of Cases
Average Number of New Cases per Year Age-Standardised Incidence Rates (ESR) per100,000 Person-Year †† AAPC (95% CI) §§
1990–2016 1990–1999 2000–2009 2010–2016 1990–2016 1990–1999 2000–2009 2010–2016
All cancers 95,228 3527 3339 3641 3634 61.2 54.6 62.6 70.3 1.37 * (1.24, 1.51)
Sex
Male 39,038 1446 1348 1487 1526 50.0 43.6 51.7 58.8 1.23 * (0.83, 1.64)
Female 56,190 2081 1991 2153 2108 72.6 66.1 73.7 81.8 1.18 * (1.03, 1.34)
Age (years)
15–19 5434 201 182 204 225 20.6 19.1 20.9 22.3 0.88 * (0.58, 1.18)
20–24 8974 332 312 326 370 31.6 27.6 33.5 35.1 1.24 * (0.83, 1.66)
25–29 15,421 571 554 548 629 50.8 43.1 53.3 60.8 1.91 * (1.65, 2.17)
30–34 25,601 948 921 963 966 80.7 71.3 81.9 95.5 1.60 * (1.41, 1.79)
35–39 39,798 1474 1369 1599 1445 122.3 112.0 123.3 137.7 1.01 * (0.67, 1.35)
Cancer types *
1. Leukaemia’s 3556 132 133 132 129 2.4 2.7 2.6 2.6 0.61 * (0.12, 1.10)
1.1 Acute lymphoid leukaemia’s 1068 40 40 39 40 0.8 0.7 0.8 0.8 0.62 (−0.14, 1.39)
1.2 Acute myeloid leukaemia’s 1502 56 62 53 50 1.0 1.0 1.0 1.0 −0.24 (−0.91, 0.43)
1.3 Chronic myeloid leukaemia’s 632 23 21 25 24 0.4 0.4 0.5 0.5 1.99 * (0.49, 3.51)
1.4 Other and unspecified leukaemia’s 354 13 11 14 14 0.2 0.2 0.2 0.3 1.51 (−0.22, 3.27)
2. Lymphomas 10,211 378 368 384 385 6.8 7.4 7.7 7.7 1.06 * (0.84, 1.27)
2.1 Non-Hodgkin lymphomas 4740 176 175 180 171 3.1 2.9 3.1 3.3 0.79 * (0.38, 1.19)
2.2 Hodgkin lymphomas 5471 203 194 204 214 3.7 3.3 3.8 4.1 1.27 * (0.87, 1.67)
3. CNS and other intracranial and
intraspinal neoplasm 4644 172 178 171 165 3.1 3.6 3.4 3.3 0.41 (−0.02, 0.85)
3.1 Astrocytoma’s † 2842 105 111 103 101 1.9 1.9 1.8 2.0 0.31 (−0.26, 0.89)
3.2 Other gliomas 938 35 36 37 31 0.6 0.6 0.6 0.6 −1.02 (−3.10, 1.10)
3.3 Ependymomas 299 11 11 11 11 0.2 0.2 0.2 0.2 −0.23 (−1.90, 1.46)
3.4 Medulloblastomas and
other PNET §
219 8 8 9 7 0.2 0.1 0.2 0.1 0.17 (−1.95, 2.34)
3.5 Other specified intracranial and
intraspinal neoplasms
81 3 3 2 3 0.1 0.1 0.0 0.1 NA
3.6 Unspecified intracranial and
intraspinal neoplasms ‡
265 10 9 9 12 0.2 0.1 0.2 0.2 2.80 * (1.17, 4.46)
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Table 1. Cont.
Population Characteristics Total Number
of Cases
Average Number of New Cases per Year Age-Standardised Incidence Rates (ESR) per100,000 Person-Year †† AAPC (95% CI) §§
1990–2016 1990–1999 2000–2009 2010–2016 1990–2016 1990–1999 2000–2009 2010–2016
4. Osseous and Chondromatous
neoplasms 1434 53 52 54 55 1.0 1.0 1.1 1.1 0.79 * (0.23, 1.36)
4.1 Osteosarcomas 547 20 21 19 20 0.4 0.4 0.4 0.4 −0.04 (−1.06, 1.00)
4.2 Chondrosarcomas 256 9 9 9 11 0.2 0.2 0.2 0.2 1.86 * (0.47, 3.37)
4.3 Ewing tumours 453 17 16 18 17 0.3 0.3 0.4 0.3 1.04 * (0.02, 2.06)
4.4 Other specified and unspecified
bone tumours 178 7 6 7 6 0.1 0.1 0.1 0.1 0.85 (−1.13, 2.86)
5. Soft tissue sarcomas 3803 141 171 134 107 2.5 3.4 2.7 2.1 −2.05 * (−2.96,
−1.14)
5.1 Fibromatous neoplasms 1057 39 46 38 31 0.7 0.8 0.7 0.6 −1.24 * (−1.91,
−0.57)
5.2 Rhabdomyosarcomas 202 7 8 7 7 0.1 0.2 0.1 0.2 −0.43 (−1.91, 1.08)
5.3.1.1 Specified soft tissue sarcomas
(excluding Kaposi sarcoma) 1599 59 62 63 50 1.0 1.0 1.1 1.0 −0.40 (−1.11, 0.31)
5.3.1.2 Kaposi sarcomas 690 26 45 17 10 0.4 0.7 0.3 0.2 −8.56 * (−12.36,
−4.61)
5.3.2 Unspecified soft
tissue sarcomas 255 9 9 10 8 0.2 0.2 0.2 0.2 0.48 (−1.12, 2.10)
6. Germ cell and
Trophoblastic neoplasms 11,620 430 333 455 534 7.8 6.7 9.1 10.7 3.41 * (2.88, 3.94)
6.1 Germ cell and trophoblastic
neoplasms of the gonads 11,076 410 312 435 515 7.3 5.2 7.9 10.0 3.57 * (3.03, 4.12)
6.2 Germ cell and trophoblastic
neoplasms of non-gonadal sites 544 20 21 21 19 0.4 0.4 0.4 0.4 0.24 (−1.00, 1.50)
7. Melanoma and skin carcinomas 16,969 628 540 692 665 11.3 10.8 13.8 13.3 1.95 * (1.45, 2.44)
7.1 Melanoma 15,987 592 508 655 622 10.2 8.3 11.3 12.0 1.92 * (1.44, 2.40)
7.2 Skin carcinomas 982 36 32 37 43 0.6 0.5 0.6 0.8 2.76 * (1.69, 3.84)
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Table 1. Cont.
Population Characteristics Total Number
of Cases
Average Number of New Cases per Year Age-Standardised Incidence Rates (ESR) per100,000 Person-Year †† AAPC (95% CI) §§
1990–2016 1990–1999 2000–2009 2010–2016 1990–2016 1990–1999 2000–2009 2010–2016
8. Carcinomas 41,703 1545 1514 1574 1547 27.8 30.3 31.5 30.9 0.90 * (0.63, 1.17)
8.1 Thyroid carcinomas 3298 122 97 124 154 2.1 1.6 2.2 3.0 3.36 * (2.88, 3.85)
8.2 Head and neck carcinomas # 1831 68 68 73 61 1.2 1.1 1.2 1.2 0.13 (−0.68, 0.94)
8.3 Carcinomas of trachea,
bronchus, and lung
2144 79 91 79 65 1.3 1.5 1.3 1.3 −0.86 * (−1.24,
−0.46)
8.4 Carcinomas of breast 18,165 673 628 708 687 11.2 10.2 11.4 13.3 1.27 * (0.75, 1.78)
8.5.1 Carcinomas of kidney 982 36 31 38 42 0.6 0.5 0.6 0.8 2.95 * (1.89, 4.01)
8.5.2 Carcinomas of bladder 439 16 17 17 15 0.3 0.3 0.3 0.3 0.13 (−1.07, 1.35)
8.5.3 Carcinomas of gonads 1279 47 64 39 36 0.8 1.0 0.7 0.7 −2.27 * (−3.81,
−0.71)
8.5.4 Carcinomas of cervix
and uterus
6088 225 247 208 220 3.8 4.0 3.4 4.3 0.34 (−0.37, 1.05)
8.6.1 Carcinomas of colon/rectum 3629 134 118 145 142 2.3 1.9 2.4 2.8 1.85 * (1.34, 2.37)
8.6.2 Carcinomas of the stomach 939 35 39 34 30 0.6 0.6 0.6 0.6 −0.35 (−1.33, 0.64)
8.6.3 Carcinomas of liver and
intrahepatic bile ducts
259 10 9 9 11 0.2 0.2 0.2 0.2 2.08 * (0.64, 3.54)
8.6.4 Carcinomas of pancreas 432 16 14 17 17 0.3 0.2 0.3 0.3 1.72 * (0.22, 3.24)
8. Carcinomas of other
ill-defined sites ¶
2218 82 93 82 67 1.4 1.5 1.4 1.3 −0.86 * (−1.44,
−0.27)
9. Miscellaneous specified
neoplasms, NOS ** 1057 39 40 38 41 0.7 0.8 0.8 0.8 0.93 * (0.06, 1.80)
10. Unspecified malignant neoplasms 231 9 10 8 7 0.2 0.2 0.2 0.1 −0.95 (−3.07, 1.20)
Abbreviations: ESR = European Standard Rates, CI = Confidence Interval, CNS = Central Nervous System, PNET = Primitive Neuro-Ectodermal Tumours, ICD-O = the International
Classification of Diseases for Oncology. * Cancers in the Netherlands Cancer Registry are coded using the ICD-O valid at the time of diagnosis; 1st edition before 1993, 2nd edition between
1993 and 2000 and 3th edition since 2001. Cancer types were grouped based on the Surveillance, Epidemiology, and End Results Program (SEER) AYA site recode adapted classification
scheme. † Including specified low-grade astrocytic tumours, glioblastomas and anaplastic astrocytoma, and astrocytoma, NOS. § Including medulloblastomas and supratentorial PNET.
‡ Including unspecified malignant intracranial and intraspinal neoplasms and unspecified benign/border intracranial and intraspinal neoplasms. # Including carcinomas of the nasopharynx,
other sites in the lip, oral cavity and pharynx, and nasal cavity, mid ear, sinuses, larynx and other ill-defined head and neck tumours. ¶ Including carcinomas of other ill-defined sites
of the genitourinary tract, gastrointestinal tract, NOS, and adrenocortical carcinomas. ** Including Wilms tumours, neuroblastoma, other paediatric and embryonal tumours, NOS,
paraganglioma and glomus tumours, other specified gonadal tumours, myeloma, mast cell, misc lymphoreticular neoplasms, NOS and other specified neoplasms, NOS. †† Incidence rates
were calculated per 100,000 person-years using the mid-year population size as person-time denominator and standardized with weights from the 1976 European Standard Population.
§§ AAPC and p-value outcomes denoted with “NA” could not be computed due to having zero counts in one or more individual years of diagnosis. * Indicates significant trends (p < 0.05).
Cancers 2020, 12, 3421 8 of 26
3.2. Cancer Type Distribution
Figure 1 displays the distribution of AYA cancers stratified by sex, age and calendar period. The data
underlying this figure are included in Table 1 and Table S1. The cancer type distribution among AYAs
differed considerably between sex and age groups. Specific for male AYAs was the large contribution
of germ cell tumours for all age groups, peaking at 44.0% in the 25–29 age group in 2010–2016.
The contribution of lymphomas decreased with age, whereas carcinomas and “melanoma and skin
carcinomas” became more prominent, increasing up to 28.0% and 20.4%, respectively, in the 35–39 age
group in 2010–2016. Of all carcinomas, most frequently diagnosed among males were colorectal and
lung carcinomas, contributing up to 8.3% and 3.8% in 2010–2016 at age 35–39, respectively (Figure 1a).
Among female AYAs, lymphomas had the largest contribution in the 15–19 age group (31.2% in
2010–2016), whereas carcinomas dominated the subsequent age groups, contributing up to 70.6% in
the 35–39 age group in 2010–2016. Of all carcinomas diagnosed in female AYAs, thyroid carcinomas
contributed most in the 15–19 and 20–24 years age groups (8.8% and 8.9%, respectively in 2010–2016).
Carcinomas of the breast, cervix, and uterus dominated the older age groups, comprising up to 43.0%
(breast) and 9.7% (cervix/uterus) of all cancers diagnosed among female AYAs aged 35–39 years in
2010–2016 (Figure 1b). Time-related changes in the distribution of AYA cancers were overall less
pronounced (≤5% between 1990–1999 and 2010–2016) for the majority of cancer types. Exception to
this were the ≥10% increases in the distribution of germ cell and trophoblastic neoplasms among male
AYAs aged older than 15–19 years.
3.3. Trends in Incidence
Overall, the incidence of AYA cancers increased significantly from 54.6 in 1990–1999 to 70.3 per
100,000 person-years in 2010–2016 (AAPC: +1.37%) and likewise increased significantly over time for
both sexes and for all age groups. Incidence rates were overall higher for female AYAs with around
22 per 100,000 person-years in each calendar period (1990–1999, 2000–2009, and 2010–2016). Rates were
higher for male AYAs aged 15–19 and 20–24 years. From age 25–29 years onward, rates became
increasingly higher for female AYAs in each calendar period (Table 1, Tables S1 and S2, and Figure 2).
Increases in incidence over time were similar for both sexes for all ages combined (AAPC: +1.23% in
males; AAPC: +1.18% in females). In both sexes, the highest increases in incidence were observed
in the 25–29 age group (AAPC: +2.09% in males; AAPC: +1.73% in females), whereas they were the
lowest in the 15–19 age group (AAPC: +0.98% in males; AAPC: +0.74% in females) (Tables S1 and S2).
For the various cancer types, most marked increases in incidence since 1990 were observed
for AYAs with “unspecified intracranial and intraspinal neoplasms” (AAPC: +2.58% in males;
AAPC: +3.00% in females), melanomas (AAPC: +2.30% in males; AAPC: +1.89% in females),
skin carcinomas (AAPC: +2.60% in males; AAPC: +2.77% in females) and carcinomas of the thyroid
(AAPC: +2.56% in males; AAPC: +3.55% in females), kidney (AAPC: +2.88% in males; AAPC: +3.01% in
females) and colorectum (AAPC: +1.88% in males; AAPC: +1.83% in females) (Table 1, Tables S1 and
S2). Significant rising trends exclusive to male AYAs were seen for chronic myeloid leukaemia’s (CML,
AAPC: +2.24%), “gonadal germ cell and trophoblastic neoplasms” (AAPC: +3.73%), and miscellaneous
specified neoplasms (AAPC: +2.32%). Increases in the incidence of “other and unspecified leukaemia’s”
(AAPC: +2.38%), chondrosarcomas (AAPC: +2.32%), “non-gonadal germ cell and trophoblastic
neoplasms” (AAPC: +1.85%) and liver (AAPC: +2.54%) and pancreas carcinomas (AAPC: +2.41%)
were seen in female AYAs only (Table 1, Tables S1 and S2). Significant declines in incidence were observed
among male AYAs with Kaposi sarcomas (AAPC: −8.42%), fibromatous neoplasms (AAPC: −2.74%)
and carcinomas of other ill-defined sites (AAPC:−4.06%), while carcinomas of the gonads (AAPC:−2.35)
and lung (AAPC: −1.17) significantly declined in females only (Table S2).
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Figure 1. Relative frequencies ( ) of cancer types according to the adolescent and young adult (AYA)
site recode classification scheme by age group and calendar period for (a) male and (b) female AYA
cancer patients diagnosed at age 15–39 years in the Netherlands between 2010–2016.
Figure 2. Age-standardised incidence and mortality rates per 100,000 person-years for (a,c) male and
(b,d) female adolescents and young adults (AYAs) diagnosed with or passed away due to cancer in
the Netherlands between 1990–2016. Rates were standardised using weights from the 1976 European
standard population. Note the non-significant average annual percentage change (AAPC) estimates in
panel c for male AYA cancer patients aged 20–24 and 25–29 years.
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3.4. Trends in Survival
The five-year relative survival of all AYAs combined improved significantly over time from 73.7%
(95%CI: 73.2, 74.1) in 1990–1999 to 86.4% (95%CI: 86.0, 86.9) in 2010–2016. Survival gains were more
prominent in male compared to female AYAs, increasing from 70.0% (95%CI: 69.2, 70.8) to 85.7%
(95%CI: 85.0, 86.4) for males (15.8% increase) and from 76.2% (95%CI: 75.6, 76.8) to 86.9% (95%CI:
86.3, 87.5) for female AYAs (10.7% increase) from 1990–1999 to 2010–2016 (Table 2, Tables S3 and S4,
and Figure 3). Survival outcomes in 2010–2016 were similarly high for most age groups around 87–90%
at five-years of follow-up for both sexes, but lagged somewhat behind in male AYAs aged 35–39 years
(80.5% [95%CI: 79.1, 81.9]) (Table 2, Tables S3 and S4, and Figure 3).
Among the various cancer types, largest improvements (>30%) in survival since 1990–1999
were observed for Kaposi sarcoma (66.5% and 55.0% increase in males and females, respectively)
and “unspecified intracranial and intraspinal neoplasms” (42.2% and 30.6% increase in males and
females, respectively). Large improvements in survival exclusive to male AYAs were observed for CML
(44.1% increase up to 95.7%), unspecified malignant neoplasms (35.5% increase up to 51.6%) and liver
carcinomas (31.0% increase up to 41.6%), whereas this was the case for Ewing sarcomas (33.0% increase
up to 66.3%) and acute lymphatic leukaemia’s (ALL, 30.6% increase up to 75.2%) for female AYAs
only. Improvements in survival were overall more prominent among male AYAs for most cancer
types (Figure 4). A significant 10.3% (p-value = 0.04) decline in bladder carcinoma survival for both
sexes combined was observed between 1990–1999 and 2010–2016, but was not significantly shown in
males and females individually (Table 2, Tables S3 and S4, and Figure 4). For several cancer types,
non-significant time-related changes in survival were observed, most prominently among females
(nine groups more compared to males) (Table 2, Tables S3 and S4).
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Table 2. Number at risk and five-year relative survival estimates with 95% confidence intervals of adolescent and young adult (AYA) cancer patients aged 15–39 years
at time of diagnosis in the Netherlands between 1990–2016 and presented by sex, age, cancer type and period of diagnosis.
Population Characteristics
Period of Diagnosis
p-Value ††1990–2016 1990–1999 2000–2009 2010–2016
n at Risk % RS (95% CI) n at Risk % RS (95% CI) n at Risk % RS (95% CI) n at Risk % RS (95% CI)
All cancers 95,228 79.9 (79.6, 80.2) 33,386 73.7 (73.2, 74.1) 36,405 81.3 (80.9, 81.7) 25,437 86.4 (86.0, 86.9) 0.00
Sex
Male 39,038 78.1 (77.7, 78.5) 13,481 70.0 (69.2, 70.8) 14,873 80.2 (79.5, 80.8) 10,684 85.7 (85.0, 86.4) 0.00
Female 56,190 81.2 (80.8, 81.5) 19,905 76.2 (75.6, 76.8) 21,532 82.2 (81.6, 82.7) 14,753 86.9 (86.3, 87.5) 0.00
Age (years)
15–19 5434 80.5 (79.4, 81.5) 1824 73.7 (71.6, 75.6) 2038 81.9 (80.2, 83.5) 1572 86.7 (84.8, 88.3) 0.00
20–24 8974 84.1 (83.3, 84.9) 3123 77.9 (76.4, 79.4) 3264 85.6 (84.3, 86.8) 2587 89.9 (88.6, 91.1) 0.00
25–29 15,421 83.2 (82.6, 83.8) 5540 77.9 (76.7, 78.9) 5477 84.1 (83.1, 85.1) 4404 89.2 (88.2, 90.2) 0.00
30–34 25,601 81.0 (80.5, 81.5) 9209 74.8 (73.9, 75.7) 9632 82.7 (82.0, 83.5) 6760 87.2 (86.4, 88.1) 0.00
35–39 39,790 76.9 (76.5, 77.3) 13,690 70.2 (69.5, 71.0) 15,994 78.6 (78.0, 79.2) 10,114 83.7 (82.9, 84.5) 0.00
Cancer types *
1. Leukaemia’s 3556 59.2 (57.5, 60.8) 1334 47.1 (44.3, 49.7) 1321 62.3 (59.6, 64.9) 901 72.9 (69.8, 75.8) 0.00
1.1 Acute lymphoid leukaemia’s 1068 56.2 (53.1, 59.2) 396 43.5 (38.5, 48.4) 391 58.4 (53.3, 63.1) 281 71.8 (65.9, 76.9) 0.00
1.2 Acute myeloid leukaemia’s 1502 48.9 (46.3, 51.4) 616 39.9 (36.0, 43.7) 533 50.6 (46.3, 54.8) 353 62.3 (56.8, 67.3) 0.00
1.3 Chronic myeloid leukaemia’s 632 78.5 (75.1, 81.6) 211 57.5 (50.5, 63.9) 254 86.9 (82.0, 90.5) 167 92.9 (87.3, 96.2) 0.00
1.4 Other and unspecified leukaemia’s 354 77.1 (72.2, 81.2) 111 80.2 (71.3, 86.7) 143 72.8 (64.7, 79.5) 100 80.0 (70.2, 86.9) 0.95
2. Lymphomas 10,211 85.7 (85.0, 86.4) 3680 78.7 (77.4, 80.0) 3837 87.5 (86.4, 88.5) 2694 93.0 (91.9, 94.0) 0.00
2.1 Non-Hodgkin lymphomas 4740 76.1 (74.9, 77.3) 1745 65.0 (62.7, 67.3) 1797 79.5 (77.5, 81.3) 1198 87.6 (85.5, 89.4) 0.00
2.2 Hodgkin lymphomas 5471 94.0 (93.3, 94.7) 1935 91.1 (89.7, 92.3) 2040 94.6 (93.5, 95.5) 1496 97.4 (96.3, 98.2) 0.00
3. CNS and other intracranial and
intraspinal neoplasm 4644 58.8 (57.3, 60.2) 1780 54.3 (51.9, 56.6) 1707 57.7 (55.3, 60.0) 1157 67.8 (64.8, 70.6) 0.00
3.1 Astrocytoma’s † 2842 51.5 (49.7, 53.4) 1110 48.0 (45.1, 51.0) 1027 49.6 (46.4, 52.6) 705 60.3 (56.3, 64.1) 0.00
3.2 Other gliomas 938 68.1 (65.0, 71.1) 355 63.4 (58.1, 68.2) 367 67.2 (62.1, 71.8) 216 78.7 (72.3, 83.9) 0.00
3.3 Ependymomas 299 84.1 (79.3, 87.9) 114 80.9 (72.3, 87.1) 110 86.6 (78.6, 91.8) 75 84.7 (73.0, 91.7) 0.27
3.4 Medulloblastomas and other PNET § 219 64.1 (57.2, 70.2) 82 65.4 (53.9, 74.7) 86 59.4 (48.3, 69.0) 51 69.3 (52.9, 80.9) 0.83
3.5 Other specified intracranial and
intraspinal neoplasms 81 61.6 (49.9, 71.3) 34 62.0 (43.6, 76.0) 24 58.5 (36.5, 75.2) 23 62.7 (38.4, 79.7) 0.77
3.6 Unspecified intracranial and
intraspinal neoplasms ‡ 265 69.4 (63.3, 74.7) 85 48.7 (37.6, 58.9) 93 73.3 (63.0, 81.2) 87 85.9 (75.4, 92.1) 0.00




p-Value ††1990–2016 1990–1999 2000–2009 2010–2016
n at Risk % RS (95% CI) n at Risk % RS (95% CI) n at Risk % RS (95% CI) n at Risk % RS (95% CI)
4. Osseous and Chondromatous neoplasms 1434 64.1 (61.5, 66.5) 515 57.5 (53.1, 61.7) 535 63.9 (59.7, 67.9) 384 73.1 (67.9, 77.6) 0.00
4.1 Osteosarcomas 547 61.2 (56.9, 65.2) 211 56.4 (49.4, 62.8) 194 60.8 (53.5, 67.3) 142 69.3 (60.3, 76.8) 0.02
4.2 Chondrosarcomas 256 82.2 (76.8, 86.5) 88 75.2 (64.7, 83.0) 90 82.3 (72.6, 88.9) 78 90.6 (81.0, 95.6) 0.01
4.3 Ewing tumours 453 48.7 (44.0, 53.3) 156 38.9 (31.2, 46.5) 178 48.7 (41.2, 55.9) 119 60.5 (50.2, 69.3) 0.00
4.4 Other specified and unspecified
bone tumours 178 85.9 (79.7, 90.3) 60 83.6 (71.5, 91.0) 73 86.5 (76.3, 92.6) 45 88.2 (73.5, 95.1) 0.57
5. Soft tissue sarcomas 3803 69.3 (67.8, 70.8) 1709 60.3 (57.9, 62.6) 1344 76.3 (73.9, 78.5) 750 77.7 (74.3, 80.7) 0.00
5.1 Fibromatous neoplasms 1057 94.9 (93.3, 96.1) 460 91.6 (88.6, 93.9) 378 96.8 (94.3, 98.3) 219 98.8 (96.0, 99.8) 0.00
5.2 Rhabdomyosarcomas 202 40.6 (33.7, 47.4) 84 35.8 (25.7, 46.0) 66 42.5 (30.5, 54.0) 52 45.3 (30.6, 58.9) 0.17
5.3.1.1 Specified soft tissue sarcomas
(excluding Kaposi sarcoma) 1599 67.8 (65.4, 70.1) 619 65.3 (61.4, 69.0) 630 69.0 (65.2, 72.5) 350 69.6 (64.2, 74.5) 0.11
5.3.1.2 Kaposi sarcomas 690 50.3 (46.4, 54.0) 452 29.8 (25.6, 34.1) 168 87.8 (81.7, 92.0) 70 96.0 (87.4, 98.9) 0.00
5.3.2 Unspecified soft tissue sarcomas 255 47.3 (40.9, 53.3) 94 41.1 (31.1, 50.9) 102 48.5 (38.5, 57.9) 59 54.6 (40.5, 66.7) 0.11
6. Germ cell and Trophoblastic neoplasms 11,620 96.9 (96.5, 97.2) 3331 95.1 (94.3, 95.8) 4551 96.8 (96.3, 97.3) 3738 98.5 (98.0, 98.9) 0.00
6.1 Germ cell and trophoblastic neoplasms
of the gonads 11,076 97.6 (97.3, 97.9) 3123 96.3 (95.5, 96.9) 4345 97.6 (97.1, 98.1) 3608 98.8 (98.3, 99.2) 0.00
6.2 Germ cell and trophoblastic neoplasms
of non-gonadal sites 544 81.7 (78.2, 84.8) 208 77.2 (70.8, 82.4) 206 80.3 (74.1, 85.1) 130 91.1 (84.2, 95.1) 0.00
7. Melanoma and skin carcinomas 16,969 92.5 (92.1, 92.9) 5400 90.0 (89.1, 90.7) 6916 92.9 (92.3, 93.5) 4653 95.1 (94.4, 95.8) 0.00
7.1 Melanoma 15,987 92.3 (91.9, 92.7) 5084 89.7 (88.8, 90.5) 6550 92.7 (92.0, 93.3) 4353 95.1 (94.3, 95.7) 0.00
7.2 Skin carcinomas 982 95.4 (93.8, 96.6) 316 93.7 (90.3, 96.0) 366 96.5 (93.9, 98.1) 300 96.0 (92.8, 97.8) 0.18
8. Carcinomas 41,703 74.8 (74.3, 75.2) 15,139 69.1 (68.4, 69.9) 15,735 75.9 (75.3, 76.6) 10,829 81.4 (80.6, 82.2) 0.00
8.1 Thyroid carcinomas 3298 98.3 (97.7, 98.7) 974 98.1 (96.9, 98.8) 1244 98.4 (97.5, 99.0) 1080 98.3 (97.2, 99.0) 0.69
8.2 Head and neck carcinomas # 1831 79.4 (77.4, 81.2) 680 73.7 (70.1, 76.8) 727 81.6 (78.5, 84.3) 424 85.1 (81.1, 88.3) 0.00
8.3 Carcinomas of trachea, bronchus,
and lung 2144 29.1 (27.2, 31.1) 905 24.2 (21.5, 27.1) 785 29.5 (26.3, 32.7) 454 37.9 (33.2, 42.6) 0.00
8.4 Carcinomas of breast 18,165 82.6 (82.1, 83.2) 6275 76.0 (74.9, 77.0) 7083 84.7 (83.8, 85.5) 4807 89.4 (88.4, 90.3) 0.00
8.5.1 Carcinomas of kidney 982 79.8 (77.1, 82.2) 305 71.8 (66.3, 76.5) 382 81.4 (77.0, 85.0) 295 86.5 (81.9, 90.1) 0.00
8.5.2 Carcinomas of bladder 439 58.0 (53.2, 62.6) 169 64.4 (56.6, 71.2) 168 53.8 (45.9, 61.0) 102 54.1 (43.5, 63.6) 0.04
8.5.3 Carcinomas of gonads 1279 66.6 (63.9, 69.1) 635 69.9 (66.1, 73.3) 392 62.9 (57.9, 67.5) 252 62.5 (55.5, 68.7) 0.07
8.5.4 Carcinomas of cervix and uterus 6088 87.2 (86.3, 88.0) 2466 86.3 (84.9, 87.7) 2079 86.7 (85.1, 88.1) 1543 89.3 (87.5, 90.9) 0.01
8.6.1 Carcinomas of colon/rectum 3629 64.1 (62.5, 65.7) 1182 59.2 (56.3, 61.9) 1450 65.8 (63.2, 68.2) 997 67.7 (64.5, 70.7) 0.00
8.6.2 Carcinomas of the stomach 939 27.4 (24.6, 30.4) 385 21.8 (17.8, 26.0) 343 30.6 (25.7, 35.6) 211 33.7 (27.2, 40.3) 0.00




p-Value ††1990–2016 1990–1999 2000–2009 2010–2016
n at Risk % RS (95% CI) n at Risk % RS (95% CI) n at Risk % RS (95% CI) n at Risk % RS (95% CI)
8.6.3 Carcinomas of liver and intrahepatic
bile ducts 259 26.6 (21.1, 32.3) 89 17.2 (10.0, 26.0) 94 24.3 (16.1, 33.4) 76 40.0 (28.0, 51.8) 0.00
8.6.4 Carcinomas of pancreas 432 29.4 (25.2, 33.8) 144 23.0 (16.5, 30.2) 166 21.4 (15.5, 27.9) 122 47.8 (38.5, 56.4) 0.00
8. Carcinomas of other ill-defined sites ¶ 2218 39.2 (37.2, 41.3) 930 31.4 (28.5, 34.5) 822 40.2 (36.8, 43.6) 466 53.1 (48.3, 57.7) 0.00
9. Miscellaneous specified neoplasms,
NOS ** 1057 71.5 (68.6, 74.2) 397 66.2 (61.3, 70.7) 375 71.9 (67.1, 76.2) 285 79.0 (73.6, 83.5) 0.00
10. Unspecified malignant neoplasms 231 32.2 (26.2, 38.3) 101 20.9 (13.6, 29.3) 84 35.5 (25.3, 45.7) 46 51.2 (35.7, 64.8) 0.00
Abbreviations: RS = Relative Survival, CI = Confidence Intervals, CNS= Central Nervous System, PNET = Primitive Neuro-Ectodermal Tumours, ICD-O = the International Classification
of Diseases for Oncology. * Cancers in the Netherlands Cancer Registry are coded using the ICD-O valid at the time of diagnosis; 1st edition before 1993, 2nd edition between 1993
and 2000 and 3th edition since 2001. Cancer types were grouped based on the Surveillance, Epidemiology, and End Results Program (SEER) AYA site recode adapted classification
scheme. † Including specified low-grade astrocytic tumours, glioblastomas and anaplastic astrocytoma, and astrocytoma, NOS. § Including medulloblastomas and supratentorial
PNET. ‡ Including unspecified malignant intracranial and intraspinal neoplasms and unspecified benign/border intracranial and intraspinal neoplasms. # Including carcinomas of the
nasopharynx, other sites in the lip, oral cavity and pharynx, and nasal cavity, mid ear, sinuses, larynx and other ill-defined head and neck tumours. ¶ Including carcinomas of other
ill-defined sites of the genitourinary tract, gastrointestinal tract, NOS, and adrenocortical carcinomas. ** Including Wilms tumours, neuroblastoma, other paediatric and embryonal
tumours, NOS, paraganglioma and glomus tumours, other specified gonadal tumours, myeloma, mast cell, misc lymphoreticular neoplasms, NOS and other specified neoplasms, NOS.
†† p-values were obtained from a likelihood ratio test comparing a generalized linear model including the midpoint of the calendar period and a model without calendar period. All models
assumed a Poisson distribution for the observed number of deaths. Significance was determined if p < 0.05.
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Figure 4. Cancer type specific changes (%) in five-year relative survival outcomes between 1990–1999
and 2010–2016 for male and female adolescent and young adult (AYA) cancer patients diagnosed in
the Netherlands between 1990–2016. p-values were obtained from a likelihood ratio test comparing a
model including the midpoint of the calendar period and a model without calendar period. A p-value
<0.05 was considered to be statistically significant (denoted with *).
Favourably high survival outcomes (>90%) in 2010–2016 were observed for all AYAs with
Hodgkin lymphomas, “gonadal germ cell and trophoblastic neoplasms”, “melanoma and skin
carcinomas”, fibromatous neoplasms, Kaposi sarcomas, and thyroid carcinomas. For male AYAs
specific, survival was also favourably high for CMLs, chondrosarcomas, and for carcinomas of the breast
and gonads (which likely relates to low case numbers), whereas survival was high for ependymomas
and “non-gonadal germ cell and trophoblastic neoplasms” in female AYAs only. For all AYAs,
survival remained poor (<60%) for rhabdomyosarcoma, unspecified soft tissue sarcomas, unspecified
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malignant neoplasms, and carcinomas of the lung, stomach, liver, pancreas, bladder and other
ill-defined sites. In males, the survival was also particularly low for astrocytoma’s, Ewing sarcomas,
and other specified intracranial and intraspinal neoplasms (Table 2, Tables S3 and S4).
3.5. Trends in Mortality
In total, 16,931 AYA cancer mortality cases were registered in the Netherlands between 1990–2016
(Table S5). Cancer mortality rates were generally higher among female AYAs. This was especially the
case for the 30–34 and 35–39 age groups, whereas the mortality was relatively higher for male AYAs
aged 15–19 and 20–24 years (Figure 2). Mortality rates for all female AYAs combined significantly
declined from 14.4 to 10.1 per 100,000 person-years (AAPC: −1.81%) between 1990–2016, whereas rates
overall declined from 10.8 to 6.6 per 100,000 person-years (AAPC: −1.64%) in males (Figure 2).
Age-specific mortality rates among female AYAs significantly declined for all age groups since 1990.
Non-significant declines in mortality were observed for male AYAs 20–24 and 25–29 years of age,
but significantly declined otherwise (Figure 2).
4. Discussion
This study provided a comprehensive overview of long-term trends in incidence, survival and
mortality among all AYA cancer patients aged 15–39 years and diagnosed in the Netherlands from 1990
through 2016. In general, the incidence of AYA cancer has increased. Meanwhile, the survival improved
and the mortality declined over time for both sexes and for all age groups. Our findings further
highlight a changing pattern in the distribution of cancer types based on AYA sex, age, and calendar
period. Although progress among AYAs has been encouraging for most cancer types, survival gains
and outcomes at five-years of follow-up remained poor (<60%) for AYAs with rhabdomyosarcoma,
unspecified soft tissue sarcomas, unspecified malignant neoplasms and carcinomas of the lung, bladder,
stomach, liver, pancreas, and other ill-defined sites.
4.1. Cancer Type Distribution
It is well-known that the spectrum of cancers in AYAs is distinct and differs considerably from
that in paediatric and older adult cancer patients [10,15,24,25]. Our data reconfirm and add to this by
also presenting the distribution of AYA cancers over time, which highlights the minimal impact that
time has had on the distribution of AYA cancers from 1990–1999 to 2010–2016. Our findings further
emphasise the importance of distinguishing AYAs based on sex and age instead of grouping them
all together for analytical purposes as the distribution of AYA cancers differs substantially based on
these factors.
4.2. Trends in Incidence
Similar to earlier findings in most countries worldwide, the incidence of AYA cancers in the
Netherlands has increased significantly since 1990 [7–9,24,25]. Rising trends in overall cancer incidence
among AYAs have been attributed to thyroid cancer overdiagnosis (detection of cancers that would not
have affected the lives of individuals during their lifetimes when left undetected) and trends stabilised
after these malignancies were excluded from the analyses, in particular for females [25,26]. In our
study, stabilisation of trends only occurred for female AYAs aged 20–24 years (AAPC: +0.53, p = 0.20)
after excluding thyroid carcinomas from the analyses. This indicates that thyroid cancer alone does
not provide a full explanation for the current rise in cancer incidence among AYAs in the Netherlands.
Another reason may be the increasing number of children (aged 0–17 years) diagnosed with cancer
in the Netherlands (incidence increased annually with 0.6% between 1990–2017) [27]. Survival of
childhood cancers is high (>80% at five-years of follow-up) and survivors have been shown to have
a higher risk of developing subsequent malignancies when compared with the general population,
including cancers typically seen in AYAs (e.g., bone and soft tissue sarcomas and breast, thyroids,
and skin carcinomas) [28]. In our study, we have included all primary cancers that were diagnosed at
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AYA age, including subsequent malignancies of those that were first diagnosed with cancer during
childhood. As such, the higher subsequent cancer risk of childhood cancer survivors likely contributes
to some extent to the rise in cancer incidence at AYA age, but we were unable to test this.
The relative higher cancer incidence rates among female AYAs have been observed worldwide and
could be explained by the extension of the upper-age-limit of AYAs from 25 to 39 years and is mainly
based on the increased incidence of so-called female cancers (i.e., breast, cervix, and uterus) [7,15,24,25].
The approximately three times higher rates of thyroid carcinoma incidence among females likely
also contributed.
4.2.1. Melanoma and Skin Carcinomas
The relative high incidence rates (approximately two times higher in females) and the noticeable
increases in melanomas and skin carcinomas among all AYAs over time likely result from increased
sun exposure and use of tanning devices, but could also reflect increased cancer awareness [29,30].
The extent to which these factors apply to the youngest AYAs could be argued, as exposure time
in this population is limited. However, greater use and earlier age at first sunbed use have been
associated with increased melanoma risk (76% of melanomas were attributed to sunbed use at age
18–29 years) in previous research [29]. It was also suggested that younger people might be more
biologically susceptible to the carcinogenic effects of artificial ultraviolet radiation [29]. Support for
this was provided in a more recent study, were mutations associated with ultraviolet radiation damage
were found at similar rates among AYAs compared with older patients [31]. Primary prevention
efforts aimed at reducing ultraviolet ray exposure have already proven effective in lowering melanoma
incidence among Australian (1998–2012) and American AYAs (2007–2016) and might also do so in
other countries, especially among those with high sunbed use [25,30].
4.2.2. Thyroid and Kidney Carcinomas
In line with previous global finding, rising trends in incidence were among the highest for AYAs
diagnosed with thyroid and kidney carcinomas and a markedly higher burden of thyroid carcinomas
was observed within the female AYA population [8,9,15,24,25]. These rising trends have been primarily
attributed to overdiagnosis [9,32,33]. There is also some evidence suggesting that exposure to ionizing
radiation (particularly in childhood) could influence the incidence of thyroid carcinomas in young
adults [34]. Still, overdiagnosis does not seem to provide a full explanation, as mortality rates of thyroid
carcinomas in the US are steadily increasing, likely due to a true rise in advanced stage papillary
thyroid cancer (1974–2013) [35]. It also remains unclear what exactly causes the higher thyroid cancer
burden among females [36]. Gaining increased genomic and proteomic knowledge is warranted, as it
may provide a solid basis to better understand the gender disparities within the AYA cancer domain.
4.2.3. Colorectal, Liver, and Pancreas Carcinomas
Worldwide, the AYA population has seen a distinct rise in incidence of colorectal
carcinomas (CRC) [8,37,38]. Rates in the general population have either been stabilizing or
are decreasing in high-income countries due to screening practices [39,40]. It is currently not
clear what causes the increase among AYAs, but it could be owing to the increased use of
colonoscopy among symptomatic cases and advances in imaging and pathological techniques [40].
Environmental factors (e.g., Western diet, smoking, and alcohol consumption) and heredity
predisposition (e.g., Lynch syndrome, familial adenomatous polyposis) have also been implicated,
although most AYA CRCs were found to be sporadic in nature [41–43]. It has been hypothesised that
AYA CRCs have a unique biology relative to those arising at older ages, but contemporary knowledge
is limited [43,44]. The rising levels of obesity might also drive some of the burden. Obesity is a
well-known risk factor associated with CRC and has also been proposed to be partly responsible for
the increase in liver and pancreas carcinomas, here observed exclusively among female AYAs [45,46].
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4.2.4. Gonadal Germ Cell Tumours
Specific to male AYAs was the high burden and prominent increase in gonadal germ cell tumours
(testis) since 1990. These findings are in line with those observed globally and highlight the large
contribution that these tumours have on the overall rising trend in incidence of cancer among males;
in fact, this group is the main explanation for this observation [8,25,47]. Although the aetiology of
these cancers in the AYA population is poorly understood, an association was found between higher
levels of neonatal androgens and increased testis cancer risk among adolescents (15–19 years), but not
infants (0–4 years) [48]. Exposure to certain persistent organochlorine pesticides during foetal life
might also increase the risk of testicular germ cell tumours [49].
4.2.5. Breast Carcinomas
Among female AYAs, the incidence of breast cancer steadily increased since 1990, but it is not well
understood what exactly drives these trends. For the older AYA age groups, the well-known lifestyle
factors often associated with increased breast cancer risk (e.g., early age at menarche, late age at first
childbearing, low number of pregnancies, not breast feeding, and exogenous hormone use) are likely
responsible in part for the increase [50]. In younger AYAs, genetic predisposition (BRCA 1/2) is likely
an important contributing risk factor for breast cancer, but also excessive alcohol consumption and
smoking habits [50]. In a 2006 meta-analysis, high breast density was found to be a strong risk factor
for breast cancer at all ages and likely also drives some of the burden [51].
4.2.6. Lung Carcinomas
Similar to other studies, an unexplained decline in lung carcinoma incidence among female
AYAs was found [8,9,26]. In contrast to existing literature, no declining trend was observed for male
AYAs, whereas this was shown in previous research in various countries worldwide (e.g., US, Canada,
Spain, etc.) between 1998–2012 [8]. However, the same paper did not observe any declines in lung
carcinomas among AYAs in the Netherlands [8]. Declines likely relate in part to the decreased rate
of tobacco smoking due to successful prevention campaigns, but considering the young age of the
AYA population, the impact of smoking in causing the disease is likely limited [9]. Moreover, there is a
relatively high percentage of AYAs with lung cancer who never smoked and have driver mutations,
such as EGFR, ALK, KRAS, and ROS1 [9,52,53]. Future research should attempt to find more likely
explanatory factors underlying these declining trends among AYAs and in general [9].
4.2.7. Kaposi Sarcoma and Non-Hodgkin Lymphoma
Historically, the human immunodeficiency virus (HIV)/acquired immune deficiency syndrome
(AIDS) epidemic in the 1980s to early 1990s lead to a marked increase in Kaposi sarcoma and
non-hodgkin lymphoma (NHL) incidence, especially among male AYAs. After the epidemic subsided
(due to improved antiretroviral treatment and HIV control), the incidence started stabilizing and
declining for all age groups, albeit much slower in AYAs [9,54]. Based on this and other studies,
the post-epidemic declines have maintained [8–10]. The large AAPC effect sizes for Kaposi sarcoma
in this study are most likely affected by the small number of cases and subsequent incidence rates
(n = 690 between 1990–2016).
4.3. Trends in Survival
Favourably high survival outcomes and promising gains among AYA cancer patients have been
reported by multiple studies worldwide and now often exceed well above 80% (here 86.4% in 2010–2016)
at five-years of follow-up [12,24,25,55]. As noted in a recent study, AYAs now demonstrate survival
gains that are at least equal to those found in paediatric and older adult patient populations and it
was concluded that the AYA survival gap has been closed. However, this was not the case for all
malignancies and disparities were reportedly increasing between various AYA subsets (e.g., stage,
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race, ethnicity, etc.) [7,12,14]. Likewise, reported gains in 10-, 20-, and 25-year overall survival among
five-year American AYA cancer survivors (treated between 1970–2005) remained overall inferior
to that of the general population [55]. Survival outcomes among AYAs might in fact also be less
favourable than those reported in the literature due to being artificially inflated by thyroid carcinoma
overdiagnosis (five-year survival approaches 100%). However, after correcting for this and for the
HIV/AIDS epidemic, Bleyer et al. reported that the overall relative survival still improved and exceeded
80% at five-years of follow-up in females and 75% in males based on data from 1975 through 2007 [9].
Consistent with these findings, exclusion of thyroid carcinomas from the survival analysis in this
study also had no apparent effect and the observed relative survival outcomes and gains among AYAs
remained favourably high.
4.3.1. Kaposi Sarcoma and Non-Hodgkin Lymphoma
As in previous studies, survival outcomes in the past (1990–1999) were around 6% higher in
female AYAs, but have become approximately equal between both sexes in 2010–2016 [12,14,55].
Lower survival outcomes among male AYAs in the past have been attributed to the increased burden of
cancers related to the HIV/AIDS epidemic, which mainly affected males and historically had among the
lowest survival outcomes (Kaposi sarcoma) [9]. The HIV/AIDS epidemic, however, does not appear to
have negatively impacted the cancer survival outcomes in this study, as exemplified by the apparent lack
in outcome changes when excluding Kaposi sarcoma and NHL from the analyses. This is not surprising
considering that the prognosis of HIV/AIDS related cancers has drastically improved following the
development of more effective treatment options, including targeted anti-CD20 immunotherapy [9,54].
This likely also resulted in the major improvements in survival of Kaposi sarcoma and HIV-related
NHL, now reaching five-year relative survival outcomes well-above 85% among all AYAs combined in
2010–2016, whereas in the past, they were usually fatal [9,54]. Similar conclusions have been drawn
elsewhere [14].
4.3.2. Gonadal Germ Cell Tumours
More likely related to the catching up of the survival among male AYAs in this study is the
increasing presence of gonadal germ cell tumours (testis) with their good prognostic outcomes (>95%).
This is evidenced by the exclusion of these tumours from the analyses, which drastically lowered
the survival outcomes among males with around 6% in 2010–2016, whereas the survival in females
remained unaffected. Although a major driver, the increase in gonadal germ cell tumours does not
provide a full explanation for the entire extent of improvements. Higher survival gains over time
among male AYAs were also observed for most other cancers including common types, such as
leukaemia’s, lymphomas, “melanoma and skin carcinomas”, and nearly all carcinomas, most of which
had better survival outcomes in female AYAs in the past, but now for most cases have become equal
for both sexes. Advances in diagnostic and treatment practices, therefore, likely also contributed.
Compared to the other sex and age groups, the five-year relative survival is still lower in male
AYAs aged 35–39 years. This likely relates to the increased presence of carcinomas with increasing age,
which overall had a much better prognosis in female AYAs, likely due to the high survival outcomes
(>80%) of female cancers (i.e., breast, uterus, and cervix cancer), which are most commonly found in
females aged 35–39 years. Recent literature also points to other factors responsible for the survival
disparities between AYA subgroups, including stage, race, and social economic status, but these were
not included in this study [14].
4.3.3. Bladder Carcinomas
Whereas the survival improved for most cancers at AYA age, there was a noticeable decline in
bladder carcinoma survival, although this was only significant for both sexes combined, likely due
to low case numbers when stratified by sex. It is unclear what exactly causes this decline or the
poor prognosis, as studies on bladder cancer at AYA age are sparse and often small in size [56,57].
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Compared to older patients, AYA bladder carcinoma patients were shown to have better cause-specific
and overall cancer survival outcomes and were more often diagnosed with low grade (75.5% vs. 48.6%)
and localised stage disease (71.6% vs. 63.6%) [58]. Other studies reported similar findings [56,57].
Among AYAs, survival outcomes were only lower for non-Hispanic African Americans with low
socioeconomic status compared with older patients [58]. However, this provides no explanation for the
consistent decline in bladder cancer survival since 1990–1999. Further studies are desperately needed
to identify the underlying causes in order to better understand and overcome the declining trend in
survival among AYA bladder cancer patients.
4.3.4. Acute Lymphatic Leukaemia
Paediatric cancer patients are often treated more aggressively and studies assessing the effect
of paediatric-inspired regimens in ALL AYA patients have reported improved survival outcomes
(more so in paediatric vs. adult centres) [8,59,60]. Impressive gains in AYA ALL patients have
likewise been demonstrated following therapeutic advances [59]. In the Netherlands, a 25% increase
in overall survival at five-years of follow-up among ALL patients aged 18–39 years was observed
from 2001–2006 through 2007–2012, which was mainly explained by the implementation of more
intensive paediatric-based chemotherapeutic regimens in 2005 [60,61]. Additionally suggested were the
increased application of allogeneic stem cell therapy and the introduction of tyrosine kinase inhibitors
since the early 2000s [60]. While survival outcomes at five-years of follow-up among AYAs with ALL
still lack behind those of paediatric ALL patients (85–90% overall survival), relative survival outcomes
have become encouragingly high around 70–75% in 2010–2016 [62].
4.3.5. Chronic Myeloid Leukaemia
The introduction of (life-long) tyrosine kinase inhibitor treatment, which specifically targets
BCR-ABL, often found in CML patients, likely also resulted in the high survival gains and favourable
outcomes that were observed for all CML patients at AYA age in this study [9,13,63].
4.3.6. Lung, Liver, Pancreas, and Stomach Carcinomas
Likely also related to therapeutic advances are the improvements in survival among AYAs with
lung, liver, pancreas, and stomach carcinomas (more prominent in males) [64–67]. Nevertheless,
survival outcomes for these cancers in AYAs have remained relatively poor (<60%), which is
characteristic for these cancer types regardless of patient age [52,68–72]. Studies focusing on young
patients (not necessarily AYAs), have shown that younger patients (aged < 50 years) with lung,
liver, pancreas, and stomach carcinomas are more often diagnosed with more aggressive disease
with higher grade, more advanced stage and higher metastatic rates when compared with older
populations [64,65,68–72]. This likely relates in part to delays in diagnosis and higher frequencies
of driver mutations (e.g., EGFR and ALK mutations in lung cancer patients) [72–74]. In addition,
survival outcomes for younger pancreatic and lung cancer patients did not improve drastically when
treated with more aggressive treatment regimens [67,75]. This might explain why younger patients,
in some studies, show similar or worse overall survival outcomes compared with older populations
even though they generally suffer from less comorbidities and are better able to resist more intensive
treatment regimens [65,68,69,72,73,76]. Considering the more aggressive disease biology and that
younger patients have more potential life-years to lose, these cancers should receive increased attention
in future research, as literature on these cancers among AYAs is scarce [9,65,71–73]. Additionally,
consideration of genetic testing might help improve survival outcomes for young lung cancer patients,
as their higher mutation rates provide suitable targets for more personalised treatment strategies [52,72].
4.3.7. Colorectal Carcinomas
Also warranting increased attention, is the limited improvement in the survival of AYA CRC
patients (<9% improvement between 1990–1999 and 2010–2016), despite being treated more aggressively
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compared to older patients [77]. Delays in diagnosis (≥6 months on average in patients aged < 40 years)
and lack of dedicated screening programmes are likely in part responsible for the higher stages of
disease often found among AYAs and could provide some explanation for the lack in progress among
AYA CRC patients in this study [43,78]. A growing body of evidence also suggests that CRCs among
AYAs are biologically different from those in older adults, exhibiting a more aggressive phenotype
exemplified by the increased prevalence of mucinous histology, signet ring cells, higher microsatellite
instability, and mismatch-repair gene mutations [43,44,78]. Adoption of screening and novel treatment
regimens incorporating the distinct tumour biology have the potential to substantially impact the
survival of AYA CRC and should be explored [43].
4.3.8. Soft Tissue and Bone Sarcomas
With the exception of Kaposi sarcoma, the survival of AYA sarcoma patients has remained
relatively poor, especially for those with rhabdomyosarcomas, which despite its chemosensitivity
has a high risk on local and distant recurrence and death [79]. It has been well established that
the survival of sarcomas decreases considerably with age, as exemplified by recent data showing
significantly worse survival outcomes for AYA compared to paediatric sarcoma patients in Europe
between 2000–2007 [12]. However, AYA age was not found to be an independent risk factor for
bone sarcoma-related death in a recent Japan study [80]. Outcome discrepancies between AYA and
paediatric patients for histologically similar sarcomas have been attributed to differences in tumour
biology, but also to differences in treatment (e.g., specific guidelines, adherence to protocols, and
treatment dose intensity) and organisation of care (e.g., care centralisation in expert centres and wide
collaborations on national and international levels) [79–82]. Compared to children, AYA sarcoma
patients also tend to have a higher stage at diagnosis resulting from patient and doctor delay and
incorrect diagnosis [79,81,83]. Low availability and enrolment of AYAs in clinical trials (5–34% in AYAs
vs. 70–80% in children) have also been implicated [79,81,84]. Addressing these factors will likely
improve clinical outcomes among AYAs and initiatives are already under way to achieve this [85].
4.4. Trends in Mortality
Promising declines in AYA cancer mortality with time have been observed since the 1970s [24,25,86].
Our analyses showed that observed mortality rates and declines over time were slightly higher among
female AYAs, particularly among those aged 30 years and above. Although not directly stated,
more prominent declines for a majority of specific cancer types among female AYAs were also observed
by Close and colleagues [24]. A higher mortality burden in females (ages 20–39 years) was reported
by Fidler et al. in 2012, and although not studied here, their investigation showed that breast and
cervix/uterus cancers were among the major contributors of cancer-related deaths among females
(25.1% and 14.3%, respectively) [15]. In contrast, a recent analyses with SEER data between 2008–2017
showed a similar 1% average decline per year for both sexes, whereas it levelled off for women aged
30–39 years, likely reflecting stabilizing breast cancer mortality trends [25]. Another recent American
study (2020) on time-related long-term mortality trends among five-year AYA cancer survivors likewise
showed no disparities between sexes at 5-, 10-, and 20-years of follow-up [86]. However, their analyses
did show marked improvements in late all-cause mortality that was mainly driven by temporal
decreases in the mortality of primary cancers, but time-related improvements were less consistent
across cancer types [86]. As suggested by the authors, these findings likely reflect improvements in
cancer therapies and refinement of treatment strategies and might help identify priority groups for
long-term surveillance to reduce late mortality from cancer [86]. Continuing monitoring of (long-term)
mortality trends among AYAs is therefore important.
4.5. Clinical Implications
AYAs have a distinct distribution of cancers and compared to earlier and older cancer patients,
exhibit unique cancer trends (e.g., the distinct rise in CRC). Underlying these trends are several
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modifiable (e.g., obesity and participation in clinical trials) and non-modifiable factors (e.g., host age,
tumour biology, and genetic predisposition). Although research efforts centred on AYA oncology have
drastically increased in the past decade following the “Closing the gap” report [1], the AYA population
is still underrepresented in cancer research and clear understanding of the underlying biological/genetic
drivers for several cancer types is still lacking. Considering that the cancer burden is increasing in
most countries worldwide and that AYAs have a large proportion of their expected lifespans remaining
(thus contributing substantially to the economy), increased focus should be directed towards improving
primary and secondary prevention of AYA cancers. To answer more complex research questions,
large prospective datasets with detailed patient, clinical, and treatment information on AYA cancer are
needed. Considering that such data resources are limited, increased efforts are needed to initiate such
data collections [87]. In line with recent recommendations, increasing availability and participation
in clinical trials by overcoming known barriers is also crucial to advance AYA oncology outcomes.
Additionally, increased collaboration between experts from paediatric and the adult oncology at both
the national and international level is needed to best address the distinct needs and challenges that this
unique population faces [7,10].
4.6. Strenghts and Limitations
Findings in this study are based on almost three decades of high-quality data, systematically obtained
by trained registrars from the population-based NCR. Use of this data can be considered a major
strength as selection bias is not present due to the inclusion of the entire Dutch population regardless
of age at the time of cancer diagnosis. Based on these data, we were able to provide a long-term
comprehensive description on trends in incidence, survival, and mortality specific to the AYA population.
Stratification in five-year age groups allowed for a detailed assessment of age-specific trends within the
AYA population, which is another major strength of this study considering that AYAs are often grouped
together, masking important age-related differences. Our study also has a number of limitations. First,
the interpretation of results for rare cancers should be done with caution as random fluctuations due
to low number of cases may erroneously appear as noteworthy trends. Second, low case numbers
during certain sub-analyses lead to the inability for various cancer types to calculate average annual
percentage change statistics. Finally, it could be that the trends observed in this study are the results
from using the entire AYA age range and all stages combined, whereas some trends might only become
apparent with more narrow age groups and individual disease stages.
5. Conclusions
As demonstrated in this study, over the past three decades there has been a considerable rise in
cancer burden among AYAs in the Netherlands. Rising trends in incidence were found for most cancer
types. The survival greatly improved and now well exceeds above 80% at five-years of follow-up for
all cancers combined and regardless of sex. However, progress was limited and survival outcomes
have remained relatively poor (<60%) for several distinct cancer types, which is of great concern given
the worldwide rise in AYA cancer incidence. Cancer mortality trends steadily declined for most AYAs
since 1990, likely due to more effective treatment options. Increased knowledge of AYA cancers and
their distinct biology is needed to better explain the unique cancer trends observed within the AYA
population and to better understand the outcome disparities observed between males and females. As
such, there is a need for more detailed studies based on comprehensive data sources that examine
individual cancer types by age, sex, and treatment patterns in AYAs with cancer. Increased focus
should also be directed towards improving AYA cancer awareness among clinicians and patients, and
the inclusion of AYAs with cancer in clinical trials to allow for better care optimisation.
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